Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRC | Q99895 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13757956 | 0.87 | — | — | |
| SCHEMBL471973 | 0.87 | CTRC (0.32) | CTRC | |
| SCHEMBL14221284 | 0.78 | CTRC (0.38) | CTRC | |
| SCHEMBL16617655 | 0.77 | — | — | |
| SCHEMBL94170 | 0.75 | — | — | |
| SCHEMBL4911960 | 0.75 | — | — | |
| SCHEMBL22324600 | 0.75 | KDM4E (0.30) | — | |
| SCHEMBL102100 | 0.72 | — | — | |
| SCHEMBL20207207 | 0.71 | — | — | |
| SCHEMBL14215442 | 0.71 | FBP1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7358356-B2 | Processes for preparation of organic compounds | ASUBIO PHARMA CO., LTD. (JP) | 2008-04-15 | — | — | US | disclosed |
| US-7358356-B2 | Processes for preparation of organic compounds | ASUBIO PHARMA CO., LTD. (JP) | 2008-04-15 | — | — | US | disclosed |
| EP-1095947-B1 | NOVEL ANTIBACTERIAL COMPOUNDS | SANKYO CO (JP) | 2007-03-14 | — | — | EP | disclosed |
| US-6844173-B2 | Strain of Streptomyces griseus | SANKYO COMPANY, LIMITED (JP) | 2005-01-18 | — | — | US | disclosed |
| EP-1319666-A1 | Novel antibacterial compounds | Sankyo Company, Limited (JP) | 2003-06-18 | — | — | EP | disclosed |
| EP-1319406-A1 | Novel antibacterial compounds | Sankyo Company, Limited (JP) | 2003-06-18 | — | — | EP | disclosed |
| US-20030069204-A1 | Strain of streptomyces | SANKYO COMPANY LIMITED (JP) | 2003-04-10 | — | — | US | disclosed |
| US-6472384-B1 | Antimicrobial compounds | SANKYO COMPANY, LIMITED (JP) | 2002-10-29 | — | — | US | disclosed |
| EP-1095947-A1 | NOVEL ANTIBACTERIAL COMPOUNDS | Sankyo Company Limited (JP) | 2001-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069204-A1 | Strain of streptomyces | O60361, CYP8B1, MRPS34 | CTRC 1102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.